MiniMed Group (MMED) awards RSUs and stock options to officer Ali Dianaty

Rhea-AI Filing Summary

MiniMed Group, Inc. reported that officer Ali Dianaty received equity-based compensation. On March 9, 2026, Dianaty was granted 13,889 performance-based RSUs, each tied to one share of MMED common stock and vesting around March 9, 2027 based on share-price performance and a divestment-related date defined in a March 1, 2026 separation agreement. On the same date, Dianaty also received 126,263 stock options with a $18.00 exercise price, expiring in 2036, vesting 33% on each of March 9, 2028 and March 9, 2029, and 34% on March 9, 2030. All holdings reported are direct and reflect compensation grants rather than open-market purchases or sales.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Dianaty Ali

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Performance-Based Restricted Stock Units	13,889	$0.00	--
Grant/Award	Employee Stock Option (Right to Buy)	126,263	$0.00	--

Holdings After Transaction: Performance-Based Restricted Stock Units — 13,889 shares (Direct); Employee Stock Option (Right to Buy) — 126,263 shares (Direct)

Footnotes (1)

1. Each performance-based restricted stock unit represents a contingent right to receive one share of MMED common stock. The performance-based restricted stock units vest on March 9, 2027, subject to MMED common stock achieving a closing price per share of at least $32.05 as of the Divestment Date (as defined in the Separation Agreement, dated March 1, 2026, by and between Medtronic Group Holding, Inc. and Kangaroo US Holdco 2, Inc.). The later of March 9, 2027 or the Divestment Date. The option vests 33% on each of March 9, 2028 and March 9, 2029, and 34% on March 9, 2030.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dianaty Ali

(Last) (First) (Middle)

C/O 18000 DEVONSHIRE STREET

(Street)

NORTHRIDGE CA 91325

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MiniMed Group, Inc. [ MMED ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
03/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Performance-Based Restricted Stock Units	(1)	03/09/2026		A		13,889		(1)	(2)	Common Stock	13,889	$0	13,889	D
Employee Stock Option (Right to Buy)	$18	03/09/2026		A		126,263		(3)	03/09/2036	Common Stock	126,263	$0	126,263	D

Explanation of Responses:

1. Each performance-based restricted stock unit represents a contingent right to receive one share of MMED common stock. The performance-based restricted stock units vest on March 9, 2027, subject to MMED common stock achieving a closing price per share of at least $32.05 as of the Divestment Date (as defined in the Separation Agreement, dated March 1, 2026, by and between Medtronic Group Holding, Inc. and Kangaroo US Holdco 2, Inc.).

2. The later of March 9, 2027 or the Divestment Date.

3. The option vests 33% on each of March 9, 2028 and March 9, 2029, and 34% on March 9, 2030.

Remarks:

EVP, Chief Product & Technology Officer

	/s/ Bryan F. Kelly, attorney-in-fact	03/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did Ali Dianaty receive from MiniMed Group (MMED)?

Ali Dianaty received equity compensation consisting of 13,889 performance-based restricted stock units and 126,263 employee stock options. Both awards are tied to MiniMed Group common stock and were granted as non-cash compensation on March 9, 2026.

How do Ali Dianaty’s performance-based RSUs in MMED vest?

Each RSU represents a right to one MMED share and vests based on performance. Vesting references March 9, 2027 and a Divestment Date defined in a March 1, 2026 separation agreement, with MMED stock needing to reach a $32.05 closing price per share.

What are the key terms of Ali Dianaty’s MiniMed (MMED) stock options?

Dianaty’s employee stock options cover 126,263 underlying MMED shares at an $18.00 exercise price. They expire on March 9, 2036 and vest 33% on March 9, 2028, 33% on March 9, 2029, and 34% on March 9, 2030, assuming continued eligibility.

Did Ali Dianaty buy or sell MiniMed (MMED) shares on the market in this filing?

No open-market purchases or sales are reported. The Form 4 shows award-type acquisitions: grants of performance-based RSUs and employee stock options, all at a zero transaction price, representing compensation rather than trading activity in MMED stock.

What performance condition applies to Ali Dianaty’s MMED performance-based RSUs?

The RSUs require MMED common stock to reach a closing price of at least $32.05 per share as of a Divestment Date. That Divestment Date is defined in a March 1, 2026 separation agreement involving Medtronic Group Holding and Kangaroo US Holdco 2.

Are Ali Dianaty’s MiniMed (MMED) equity awards held directly or indirectly?

The filing classifies all reported holdings as direct ownership. Both the performance-based restricted stock units and the stock options are shown with direct ownership codes, with no indication of intermediary entities or indirect beneficial ownership structures.